All 2012 Releases
 |
Santarus Announces Presentation of UCERIS Phase III Extended Use Data at Digestive Disease Week Meeting
May 18, 2012
|
16.9 KB |
|
| |
SAN DIEGO--(BUSINESS WIRE)--
Santarus,
Inc. (NASDAQ: SNTS) today announced that safety and efficacy data
from a Phase III, double-blind, multicenter, placebo-controlled 12 month
extended use study with the investigational drug UCERIS™
(budesonide) 6 mg tablets (previously referred to as budesonide ...
|
|
Santarus Reports First Quarter 2012 Financial Results
May 8, 2012
|
31.3 KB |
|
| |
Total revenues of $45.9 million more than double compared with the
prior year period
Affirms 2012 financial outlook
SAN DIEGO--(BUSINESS WIRE)--
Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company,
today reported financial and operating results for t...
|
|
Santarus to Present at Bank of America Merrill Lynch 2012 Health Care Conference
May 7, 2012
|
13.8 KB |
|
| |
SAN DIEGO--(BUSINESS WIRE)--
Santarus,
Inc. (NASDAQ: SNTS) today announced that Wendell Wierenga, Ph.D.,
executive vice president, research and development, will make a
presentation at the Bank of America Merrill Lynch 2012 Health Care
Conference on Tuesday, May 15, 2012, at 2:20 p.m. Pacific time (5:20
...
|
|
Santarus to Hold First Quarter 2012 Financial Results Conference Call on May 8
Apr 26, 2012
|
12.2 KB |
|
| |
SAN DIEGO--(BUSINESS WIRE)--
Santarus, Inc. (NASDAQ: SNTS) today announced that it will release first
quarter 2012 financial results after market close on Tuesday, May 8,
2012. Santarus management will host an investment-community conference
call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss the
...
|
|
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
Apr 10, 2012
|
14.0 KB |
|
| |
SAN DIEGO--(BUSINESS WIRE)--
Santarus, Inc. (NASDAQ: SNTS) today announced the appointment of
Alessandro E. Della Chà and Matthew W. Strobeck, Ph.D., to the company's
board of directors, increasing its board membership to nine.
"We welcome our new board members and look forward to drawing on ...
|
|
Santarus to Present at 11th Annual Needham Healthcare Conference
Mar 28, 2012
|
13.4 KB |
|
| |
SAN DIEGO--(BUSINESS WIRE)--
Santarus, Inc. (NASDAQ: SNTS) today announced that Gerald T. Proehl,
president and chief executive officer, will make a presentation at the 11th
Annual Needham Healthcare Conference on Wednesday, April 4, 2012, at
10:00 a.m. Eastern time (7:00 a.m. Pacific time) at the New York Palace...
|
|
Santarus Reports Fourth Quarter and Full Year 2011 Financial Results
Mar 5, 2012
|
34.2 KB |
|
| |
2011 fourth quarter revenues of $42.6 million grew 65% over prior
year period
2011 revenues totaled $118.8 million with net income of $4.7 million
or $0.07 per diluted share
SAN DIEGO--(BUSINESS WIRE)--
Santarus,
Inc. (NASDAQ: SNTS) today reported financial ...
|
|
Santarus to Present at March Investment Conferences
Feb 29, 2012
|
13.7 KB |
|
| |
SAN DIEGO--(BUSINESS WIRE)--
Santarus, Inc. (NASDAQ: SNTS) today announced that Gerald T. Proehl,
president and chief executive officer, will make presentations at the
following investment conferences:
Cowen and Company 32nd Annual Health Care Conference on
Wednesday, March ...
|
|
Santarus to Hold Fourth Quarter and Full Year 2011 Financial Results Conference Call on March 5
Feb 27, 2012
|
13.7 KB |
|
| |
SAN DIEGO--(BUSINESS WIRE)--
Santarus, Inc. (NASDAQ: SNTS) today announced that it will release
fourth quarter and full year 2011 financial results after market close
on Monday, March 5, 2012. Santarus management will host an
investment-community conference call at 4:30 p.m. Eastern time (1:30
p.m. Pacif...
|
|
Santarus and Depomed Announce Settlement with Lupin of GLUMETZA Patent Litigation
Feb 22, 2012
|
14.8 KB |
|
| |
SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)--
Santarus, Inc. (NASDAQ:SNTS) and Depomed, Inc. (NASDAQ:DEPO) today
announced that they have entered into a settlement agreement with Lupin
Ltd. and its subsidiary, Lupin Pharmaceuticals, Inc., to resolve pending
patent litigation involving GLUMETZA® (extended...
|
|
Santarus Announces FDA Acceptance of UCERIS New Drug Application for Induction of Remission of Active Ulcerative Colitis
Feb 15, 2012
|
15.6 KB |
|
| |
FDA action date in October 2012
SAN DIEGO--(BUSINESS WIRE)--
Santarus, Inc. (NASDAQ: SNTS) today announced that the U.S. Food
and Drug Administration (FDA) has accepted for filing the company's New
Drug Application (NDA) for UCERIS™ (budesonide) tablets 9 mg.
Pursuant to Presc...
|
|
Santarus Increases Revolving Line of Credit to $35 Million and Extends Maturity to February 2015
Feb 14, 2012
|
13.6 KB |
|
| |
SAN DIEGO--(BUSINESS WIRE)--
Santarus, Inc. (NASDAQ: SNTS) today announced that it has increased its
revolving line of credit with Comerica Bank from $25 million to $35
million and extended the maturity from July 11, 2013 to February 13,
2015. In addition, Santarus has improved the interest terms on
outs...
|
|
Santarus Announces Initiation of Phase IIIb Study with UCERIS in Patients with Mild or Moderate Active Ulcerative Colitis
Feb 13, 2012
|
16.1 KB |
|
| |
UCERIS 9 mg to be evaluated as add-on therapy to oral 5-ASA drugs
SAN DIEGO--(BUSINESS WIRE)--
Santarus,
Inc. (NASDAQ: SNTS) today announced that it has begun patient
enrollment in a multicenter, randomized, double-blind,
placebo-controlled Phase IIIb clinical study with the investi...
|
|
Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE
Feb 6, 2012
|
15.9 KB |
|
| |
Completes sales force expansion to 150 representatives
SAN DIEGO--(BUSINESS WIRE)--
Santarus, Inc. (NASDAQ: SNTS) today announced that it has
commenced promotion of prescription FENOGLIDE® (fenofibrate)
tablets 40 mg and 120 mg to selected physicians in the U.S. FENOGLIDE is
in...
|
|
|
=add release to Briefcase